CUPERTINO, Calif., Jan 4, 2002 /PRNewswire via COMTEX/ — DURECT Corporation
(Nasdaq: DRRX) announced today that it will present at the JPMorgan H&Q 20th
Annual Healthcare Conference. The conference is taking place January 7-10th at
The Westin St. Francis Hotel in San Francisco. James E. Brown, DVM, Chief
Executive Officer will be presenting at the conference on Monday, January 7,
2002 at 9:30 a.m. Pacific Time.
There will a live webcast of the presentation from the Conference. The webcast
will be available on DURECT’s website at http://www.www.durect.com under the
Calendar of Events section of “Investor Relations.” The presentation will also
be available for replay on DURECT’s website for a period of 30 days after the
DURECT Corporation is pioneering the development and commercialization of
pharmaceutical systems for the treatment of chronic debilitating diseases and
enabling biotechnology-based pharmaceutical products. DURECT’s goal is to
deliver the right drug to the right site in the right amount at the right time.
DURECT’s pharmaceutical systems combine technology innovations from the medical
device and drug delivery industries with proprietary pharmaceutical and
biotechnology drug formulations. These capabilities can enable new drug
therapies or optimize existing therapies based on a broad range of compounds,
including small molecule pharmaceuticals as well as biotechnology molecules such
as proteins, peptides and genes. DURECT focuses on the treatment of chronic
diseases including pain, CNS disorders, cardiovascular disease and cancer.
DURECT holds an exclusive license from ALZA Corporation to develop and
commercialize products in selected fields based on the DUROS(R) implant
technology. Chronogesic(TM), a 3-month continuous infusion subcutaneous implant
for the treatment of chronic pain, is the first product in this series and
completed phase II testing in June 2001. DURECT also owns three proprietary
erodible implant platform technologies, including SABER(TM) (a patented and
versatile depot injectable useful for protein delivery), microspheres and
drug-loaded implants. DURECT also commercializes ALZET(R) Osmotic Pumps for
research animal use, IntraEAR(R) catheters which have been used by physicians to
treat inner ear disorders and PLGA based biodegradable polymers.
Founded in 1998, DURECT is headquartered in Cupertino, CA. The company’s World
Wide Web site can be accessed at http://www.www.durect.com . To join DURECT’s email
alert service, please register by selecting “Email Alerts” on the main Investor
Relations web page.
NOTE: Chronogesic(TM), SABER(TM) and IntraEAR(R) are trademarks of DURECT
Corporation. DUROS(R) is a trademark of ALZA Corporation.
The statements in this press release regarding DURECT’s products in development,
expected product benefits, product development plans or potential product
markets are forward-looking statements involving risks and uncertainties that
could cause actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties include, but are
not limited to, DURECT’s ability to research, develop, manufacture and
commercialize its products, obtain product and manufacturing approvals from
regulatory agencies, validate and qualify a manufacturing facility and manage
its growth and expenses, as well as marketplace acceptance of DURECT’s products.
Further information regarding these and other risks is included in DURECT’s
Quarterly Report on Form 10-Q for the quarter ended September 30, 2001 filed
with the SEC on November 13, 2001, and Annual Report on Form 10-K for the fiscal
year ended December 31, 2000 filed with the SEC on March 30, 2001, under the
heading “Factors that may affect future results.” Chronogesic(TM) is under
development by DURECT and has not been submitted or approved for
commercialization by the US Food and Drug Administration or other health
MAKE YOUR OPINION COUNT – Click Here
SOURCE DURECT Corporation
CONTACT: Schond L. Greenway, Senior Director, Investor Relations and
Strategic Planning of DURECT Corporation, +1-408-777-1417, or
Copyright (C) 2002 PR Newswire. All rights reserved.